Objectives. To measure disparities in hepatitis B virus (HBV) infection and immunity among a high-risk patient population at a community health center in New York City.
A n estimated 257 million people in the world are living with chronic hepatitis B virus (HBV) infection, 1 the world's leading cause of liver cancer. Two thirds of those chronically infected in the United States are unaware of their status. 2 Universal childhood vaccination programs since the 1980s have sharply reduced new HBV infections in regions with high HBV endemicity while increasing immunity from vaccination. [3] [4] [5] [6] Yet, an estimated one third of the world's population still has a history of infection. 1 In the United States, HBV infection is a significant racial health disparity, with Asian Americans and Pacific Islanders making up more than 50% of those with HBV infection. 7, 8 Approximately 10% of Asian American and Pacific Islander adults are chronically infected with HBV, 7 compared with fewer than 0.3% of the overall US population. 9 If unmonitored and untreated, 1 in 4 will die prematurely from liver failure or liver cancer associated with HBV infection. 10 Charles B. Wang Community Health Center (Health Center) is a federally qualified health center in New York City that serves a primarily low-income Asian population and provides multidisciplinary care. The Health Center has a patient population with a high burden of HBV infection 11 and tracks more than 8000 patients in a chronic HBV registry. Its Hepatitis B Program coordinates comprehensive and culturally appropriate HBV services and provides care management for patients with chronic HBV infection who are pregnant, uninsured and deemed high-risk, or require treatment. The Health Center was able to augment its work in hepatitis B with the adoption of an electronic medical record system so that HBV-infected patients could be systematically identified, registries created, and HBV-directed modifications made to prompt screening and regular HBV care. The Health Center implemented universal HBV screening with HBV total core antibody (anti-HBc) in addition to HBV surface antigen (HBsAg) and HBV surface antibody (anti-HBs) through its electronic medical record HBV serology order set to assess complete HBV status. In earlier years, testing was often done with only HBsAg and anti-HBs, partly because of expense and the complex serological interpretation that resulted. However, this practice changed with rising awareness of the importance of identifying those with prior infection and the known high rates of HBV exposure in foreign-born persons. 12, 13 Growing data showed that covalently closed circular DNA of HBV remains in individuals even after resolving their natural infection, and reactivation of HBV with the risk of fulminant liver failure can occur in the setting of immunocompromise, such as with chemotherapy or other immunosuppressive treatments. 14, 15 Furthermore, counseling for those with prior HBV infection (HBsAg-negative and anti-HBc-positive) was modified to discuss the small risk for HBV reactivation on immunosuppressive therapy. 14 The purpose of this study was to measure disparities in HBV infection and immunity among a high-risk patient population at a community health center in New York City by using HBsAg, anti-HBs, and anti-HBc screening tests.
METHODS
We performed a retrospective chart review of adults screened at the Health Center with HBV serology tests-HBsAg, anti-HBs, and anti-HBc-available from 1997 to 2017. We abstracted additional demographic, clinical, and laboratory information from the Health Center's GE Centricity Practice Solution version 12.0 electronic medical record system (General Electric Company, Boston, MA). We generated and managed the patient-level, de-identified data set with Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA).
We included patients aged 18 years and older with all 3 HBV serology tests in this study. If any test result was indeterminate, we excluded the patient.
Serology Test Interpretation
Results were expressed qualitatively as positive (or reactive) and negative (or nonreactive) for HBsAg, anti-HBs, and anti-HBc. Although quantitative results were not analyzed, the laboratory threshold used for a positive anti-HBs test was greater than or equal to 10 milli-International Units per milliliter. 16 We defined patient status on the basis of serology results: current infection, prior infection, ever infection, immune by vaccination, or susceptible. Current infection included all HBsAg-positive patients. Prior infection included all patients with HBsAgnegative and anti-HBc-positive results, with either a positive or negative anti-HBs. Ever infection included all patients with an anti-HBc-positive result, which included those with current or prior infection. Immune by vaccination included patients with an anti-HBs-positive result and negative HBsAg and anti-HBc results. We defined patients with a negative result for all 3 serology tests as susceptible.
Descriptive Analysis
We reported the HBV infection and immunity status of our screening population by various characteristics including family history of HBV, patient's sex, birth year, age, region of birth, preferred language, and insurance, 
Statistical Analysis
We performed c 2 analysis to determine significant differences between subgroups and multivariable models using independent variables that were statistically significant (P < .01) in univariable analyses to calculate adjusted odds ratios (AORs) and 95% confidence intervals (CIs). We analyzed age as a continuous variable and excluded birth year for overlapping with age. We used multivariable models to determine if variables remained significant after adjusting for interaction and confounding variables. We excluded patients with missing data for 1 or more of the independent variables from the multivariable models. We conducted all statistical analyses with SPSS version 23 (IBM Corporation, Armonk, NY). There were 773 household contacts of pregnant women with chronic HBV screened through the NYCDOHMH referral program, and, of those, 21.7% (n = 168) were currently infected, 70.4% (n = 544) were ever infected, and 11.1% (n = 86) were susceptible. Spouses or partners made up 89.7% (n = 693) of the group with 3.4% (n = 26) siblings, 3.0% (n = 23) parents, 2.2% (n = 17) other relatives or housemates, 0.3% (n = 2) children, and 1.4% (n = 11) unknown.
RESULTS

Data
Among the 431 (1.7%) patients with a family history of HBV, 48.5% (n = 209) had current HBV infection and 75.6% (n = 326) were ever infected.
Men, compared with women, had higher current (16.5% vs 11.1%; P < .01) and ever HBV infection (56.9% vs 48.4%; P < .01) and lower immunity from vaccination (28.5% vs 37.1%; P < .01).
Birth year analysis revealed a sharp decrease in ever HBV infection in Chinaborn individuals born after 1980 with Continued a corresponding increase in immunity from vaccination ( Figure 1 ), whereas among US-born individuals born after 1985, immunity from vaccination appeared to decrease with an increase in susceptibility ( Figure 1 ). Compared with foreign-born adults, HBV ever infection in US-born adults was significantly lower (8.7% vs 55.1%; P < .01) and immunity from vaccination (59.9% vs 31.6%; P < .01) and susceptibility (31.4% vs 13.2%; P < .01) were higher. Among the Asian countries included in this study, Hong Kong, Indonesia, and Malaysia had lower HBV ever infection (30.0%, 28.2%, and 25.1%, respectively) compared with China, Vietnam, and Taiwan (61.2%, 53.3%, and 49.3%, respectively).
Among 18 664 adults born in China, 95.7% (17 863) reported a Chinese region of birth. More than half of China-born adults were born in Fujian province (51.5%), which also had the highest proportion of patients with history of ever HBV infection (74.6%) and more than double the proportion of HBV current infection (23.5%) compared with surrounding provinces such as Guangdong (9.8%) and Zhejiang (9.3%; Table 1 and Figure 2) .
Compared with the China-born adults, the US-born adults were significantly younger (mean age 31.8 years vs 44.7 years; P < .01). Among US-born adults, ever infection was highest in individuals aged 50 to 64 years (14.0%) whereas immunity from vaccination was highest in individuals aged 18 to 34 years (69.4%; Table 1 ). Among China-born adults, individuals aged 35 to 49 years had the highest proportion of ever HBV infection (71.5%) and current HBV infection (22.2%) and individuals aged 18 to 34 years had the highest proportion of immunity from vaccination (Table 1) .
Compared with patients who preferred English, patients who preferred a non-English language had higher HBV ever infection (55.4% vs 17.1%; P < .01) and current infection (13.6% vs 4.2%; P < .01) and lower immunity from vaccination (33.2% vs 49.1%; P < .01). Compared with patients who preferred Cantonese, patients who preferred Mandarin had higher ever HBV infection (60.0% vs 47.6%; P < .01) and current HBV infection (16.2% vs 8.4%; P < .01) and lower immunity from vaccination (30.2% vs 39.8%; P < .01).
Current HBV infection was higher among the uninsured compared with insured patients (17.2% vs 11.6%; P < .01). Compared with patients with Medicare or Medicaid, patients with private insurance had lower ever HBV infection (30.1% vs 51.2%; P < .01) and current HBV infection (6.9% vs 12.3%; P < .01) and higher immunity from vaccination (51.1% vs 34.9%; P < .01). Table 2 shows results from the multivariable model for HBV infection and immunity. Male sex, birth in China, Mandarin as a preferred language, Medicaid or no insurance, and family history of HBV were associated with greater odds of current infection when we performed the multivariable model (P < .01), whereas age, Cantonese as a preferred language, and Medicare insurance were not (Table 2) . Older age, male sex, birth in China, Mandarin or Cantonese as a preferred language, Medicaid or no insurance, and family history of HBV were associated with greater odds of ever infection (Table 2) . Conversely, older age, male sex, birth in China, Medicaid or no insurance, and family history of HBV were associated with lesser odds for HBV immunity from vaccination, whereas Cantonese dialect was associated with a greater odds for HBV immunity compared with English ( Table 2) . The model showed significant interaction between region of birth and age.
Factors Associated With Hepatitis B Infection and Immunity
DISCUSSION
Data from our community health center demonstrate a high burden of HBV infection among foreign-born persons from Asia. 
Although vaccination programs in the United
States and globally have decreased the incidence of HBV, especially among younger adults from regions of high prevalence where immunity from vaccination is rising, 6,17 our data show that more than half of our community health center patients have been infected with HBV infection in their lifetime. This is a major health disparity given that HBV ever infection in the general US population is reported at about 5% from the National Health and Nutrition Examination Survey data. 18 These high rates of infection in Asian Americans from our community health center cannot be overlooked given the increasing rates of liver cancer in the United States 19 and the risk of HBV reactivation in those with prior infection who are immunosuppressed.
This high burden of current and ever HBV infection detected in foreign-born individuals, patients with limited English proficiency, and patients with Medicaid or no insurance highlights the need to test and link to care or vaccinate immigrant populations in the United States to prevent further HBV transmission and mortality from sequelae of chronic HBV. 2, 12, 20 Recruitment of language-concordant staff, use of patient navigators, professional interpreters, and collaboration with community-based organizations can help address linguistic and cultural barriers to HBV testing and linkage to care. 21 With Asia most represented in the region of birth of our foreign-born population, China, Vietnam, and Taiwan had the highest proportion of HBsAg-positive individuals, reflecting HBV prevalence cited in previous literature. 7 The increased odds of current and ever infection in individuals who preferred Mandarin dialect likely reflects the 58.1% of individuals in this group from Fujian province, the Chinese region with the highest burden of HBV infection in our study. Meanwhile, the increased odds of immunity from vaccination among those who preferred the Cantonese dialect likely reflects individuals in this group from Hong Kong and Malaysia, regions with relatively lower HBV infection.
The high burden of current (21.7%) and ever infection (70.4%) among household contacts and those with a family history of HBV highlight the priority of screening these groups as recommended by the Centers for Disease Control and Prevention (CDC). 8, 22, 23 The low percentage of patients who reported a known family history of HBV is reflective of how the disease goes unrecognized within families and households in endemic countries where vertical and horizontal transmission are most common. 1 As a result, HBV-prevention strategies should include HBV testing of all close contacts of HBsAg-positive patients followed by appropriate linkage to care including hepatitis B vaccination to prevent future transmission. 8 Our birth year analysis reflects effective implementation of hepatitis B vaccination programs in high-prevalence regions such as China, with a sharp decline in the proportion of anti-HBc-positive patients born after 1980. 4, 5, 24 However, our regression analysis showed no significant association between age and current infection. This may be attributable to selective HBV testing among younger adults with high-risk criteria other than country of origin, such as high-risk sexual behavior or injection drug use.
In addition, the decline in anti-HBs greater than or equal to 10 milli-International Units per milliliter among US-born persons born after 1985 in our birth year analysis is concerning. This may be attributable to waning anti-HBs titers rather than a reflection of decreased immunity, 25 ,26 a possible decrease in vaccination, or because US-born persons were screened after risk assessment and may not represent the general population of this age group. Because HBV vaccination coverage among children in the United States is greater than 90%, 27 this is most likely attributable to waning anti-HBs titers.
In one study, a single challenge dose of HBV vaccine in children vaccinated and found to have anti-HBs levels less than 10 milli-International Units per milliliter 6 to 18 years later resulted in anti-HBs levels greater than or equal to 10 milli-International Units per milliliter in 60% to 97% of those tested. 28 As a result, CDC recommends that immunocompetent persons with a response greater than or equal to 10 milli-International Units per milliliter following a challenge dose are considered protected, regardless of subsequent declines in anti-HBs. 29 By contrast, the persistence of anti-HBs from previous vaccination among China-born persons born after 1980 may reflect higher vaccine coverage, differences in vaccine used, or natural boosting of anti-HBs titers from HBV exposure in regions where HBV is more prevalent.
With almost 20 000 adults screened from China and routine collection of Chinese province, municipality, or region of birth, we were able to illustrate regional differences in HBV infection for 19 Chinese provinces or municipalities. Previous epidemiological studies published in China revealed the northwest and southeast regions as having the highest HBV prevalence, 22, 30, 31 whereas our study showed the highest burden of chronic HBV in the southeast region. Patients from the northwest regions of China were underrepresented in this study, which may have skewed the regional distribution and patterns of HBsAg and anti-HBc positivity toward the southeast region.
The high HBsAg positivity (23.5%) among persons born in Fujian province, more than twice that of surrounding provinces, has been reported in a single-center study in Fuzhou, China, 32 as well as a study of Chinese immigrants screened and linked to care in New York City. 33 Given the large sample size of persons from Fujian province, this high prevalence is less likely attributed to inadequate sampling. Chinese immigrants from Fujian province to New York City between Note. AOR = adjusted odds ratio; CI = confidence interval; HBV = hepatitis B virus. The sample size was n = 19 831. Patients missing at least 1 of the 6 independent variables were excluded in the multivariable logistic regression. All odds ratios were adjusted for only the independent variables of interest: age, sex, region of birth, language preference, insurance, reported family history of HBV.
a Age is a continuous variable.
AJPH OPEN-THEMED RESEARCH the late 1980s and early 2000s primarily migrated from a cluster of rural villages along the coast of Fuzhou city, Fujian province's capital city. 34 The high burden of HBV infection among China-born individuals aged 35 to 49 years in our age group analysis likely reflects this migration wave of immigrants from Fujian province. Demographic analysis of patients from Fujian province revealed a majority with low socioeconomic background including 44.2% uninsured, 32.1% unemployed, and 58.2% with high-school or lower education level. The high proportion of HBV infection among the uninsured population may reflect a larger proportion of patients from Fujian province in this group.
Our study has important limitations. Although the majority of adults received complete HBV screening, as this was a single-center study and a patient population that is predominantly high-risk for HBV, our screening results are not generalizable to the US community health screening population. However, they do highlight the high burden of HBV exposure in the Asian population, and this racial health disparity is often overlooked in many health care settings.
As this was a retrospective study, we were unable to determine if those classified as susceptible had undetectable anti-HBs titers from previous vaccination and would mount an anamnestic response if re-exposed to a challenge dose of HBV vaccine as most patients do not receive postvaccination serology testing as standard of care. In addition, as this was a retrospective analysis, we used odds ratio as a measure of association, which may overestimate the magnitude of association as hepatitis B is common in this population. Our rates of HBV current and ever infection were remarkably high among persons who were household contacts or had a family history of chronic HBV, yet this history is often not ascertained by clinicians.
Finally, about 53.1% (29 305) of patients with HBV testing were not included, almost entirely (95%) because of missing the anti-HBc test; thus, we could not determine previous infection. This was because of previous screening norms of testing with only the HBsAg and anti-HBs tests. We examined the current infection rate in this excluded group to be similar to that of patients with all 3 HBV tests (12.6% vs 13.4%). Demographic characteristics of patients with HBsAg and anti-HBs tests only were also similar (mean age 44.5 years and range 18 to 101 years, 67.2% female, 91% foreign-born, 76.9% from China, and 26% uninsured); thus, selection bias was less likely. The 275 patients with indeterminate results for any of the 3 HBV serologies excluded from our analysis represented only 1.1% of the general population and were unlikely to have significantly skewed the distribution of HBV status categories.
Our study demonstrated health disparities among foreign-born patients seeking care at our community health center as we found a higher burden of current and prior infection among Asia-born patients compared with US-born patients. To address this disparity, we assess all Asian patients for HBV risk and screen all patients born in countries with greater than 2% HBV prevalence to appropriately characterize their HBV clinical status to target HBV care and prevention. Our HBV screening of high-risk patients takes place within a primary care setting where risk assessment can be done with languageconcordant staff, and patients are already linked to chronic HBV care or HBV vaccination if needed, regardless of insurance status.
In addition, our data support the recommendation for complete HBV testing with HBsAg, anti-HBs, and anti-HBc as best practice 35 to identify and manage patients with current HBV infection, counsel those at risk for HBV reactivation, or vaccinate those susceptible to HBV infection. Furthermore, more than half of our patients have been counseled on the risk of HBV reactivation in the setting of immunosuppressive medications, including those testing anti-HBcpositive. Without anti-HBc testing, it would not be possible to determine this risk.
Chronic HBV remains one of the main contributors to the increasing rates of liver cancer and is a significant racial health disparity in the United States, disproportionately affecting Asian Americans and Pacific Islanders. Scaling up screening is a critical step toward HBV elimination-it aids in the prevention of new infections in those susceptible, identification of those who are at risk for reactivation, and linkage to essential care and treatment to the millions who are infected yet remain unaware.
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